What are the current guidelines for screening, diagnosis, treatment, and follow‑up of hereditary hemochromatosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hereditary Hemochromatosis: Screening, Diagnosis, Treatment, and Follow-Up Guidelines

Screening Recommendations

Routine population-wide screening for hereditary hemochromatosis is not recommended, but targeted case-finding should be performed in high-risk individuals. 1, 2

Who Should Be Screened:

  • First-degree relatives of patients with confirmed hemochromatosis should undergo both HFE genetic testing (C282Y and H63D) and simultaneous phenotypic screening with transferrin saturation and serum ferritin 2, 3
  • One-time screening of asymptomatic non-Hispanic white men has the highest yield among general population screening strategies 1, 2
  • Patients with suggestive clinical manifestations including fatigue, right-upper-quadrant discomfort, metacarpophalangeal joint arthralgia, sexual dysfunction, heart failure symptoms, diabetes, hepatomegaly, skin hyperpigmentation, testicular atrophy, or unexplained elevated liver enzymes 2
  • Siblings have the highest screening yield (33% C282Y homozygosity) compared to all first-degree relatives (23%) 3

Diagnostic Algorithm

Step 1: Initial Laboratory Testing

Measure transferrin saturation and serum ferritin simultaneously—never rely on a single test. 2, 3

  • Diagnostic thresholds triggering further evaluation:

    • Transferrin saturation ≥45% 2
    • Serum ferritin >300 μg/L in men or >200 μg/L in women 1, 2, 3
  • Transferrin saturation is the most sensitive early marker and should be calculated as serum iron/total iron-binding capacity × 100 2

  • Combined TS and ferritin provide optimal diagnostic accuracy with 97% negative predictive value when both are normal in individuals <35 years 2

Step 2: Genetic Testing

If either TS ≥45% or ferritin exceeds sex-specific thresholds, immediately order HFE mutation analysis for C282Y and H63D variants. 2, 3

  • C282Y homozygosity (C282Y/C282Y) confirms HFE-related hemochromatosis and accounts for 85-90% of clinically affected patients 2, 4
  • Compound heterozygotes (C282Y/H63D) have lower penetrance and require individualized assessment based on iron studies rather than genotype alone 2

Step 3: Pre-Test Genetic Counseling

Before ordering genetic testing, discuss with patients: 2

  • Efficacy and availability of phlebotomy treatment
  • Costs of testing and ongoing monitoring
  • Implications for insurability and employment
  • Psychological impact of disease labeling
  • Family screening implications
  • Possibility of uncertain or variant genotypes

Step 4: Assessment for Advanced Disease

Liver biopsy is indicated when any of the following are present: 2, 3

  • Serum ferritin >1,000 μg/L
  • Elevated transaminases (ALT/AST)
  • Palpable hepatomegaly
  • Age >40 years in C282Y homozygotes
  • Platelet count <200 × 10⁹/L

The combination of ferritin >1,000 μg/L, elevated ALT/AST, and platelets <200 predicts cirrhosis in 80% of C282Y homozygotes. 2


Important Diagnostic Pitfalls

  • Ferritin can be falsely elevated due to inflammation, chronic liver disease, malignancy, non-alcoholic fatty liver disease, metabolic syndrome, and lymphomas—these must be excluded before attributing elevation to hemochromatosis 2, 3
  • Normal ferritin does not exclude hemochromatosis in younger individuals, as only 70% of C282Y homozygotes exhibit elevated ferritin 2
  • Transferrin saturation has biological variability—repeat testing to confirm abnormalities 2
  • A normal TS with elevated ferritin may still indicate iron overload in non-HFE hemochromatosis or C282Y/H63D compound heterozygotes 2

Treatment

Phlebotomy Protocol

Therapeutic phlebotomy is the mainstay of treatment for confirmed hemochromatosis with iron overload. 3, 4, 5

  • Remove one unit (approximately 500 mL) of blood weekly or biweekly during the induction phase 2
  • Monitor hemoglobin/hematocrit before each phlebotomy to prevent anemia 2
  • Check serum ferritin every 10-12 phlebotomies during induction 2
  • Target serum ferritin of 50-100 μg/L for optimal iron depletion 2
  • Once target ferritin is achieved, transition to maintenance phlebotomy with frequency guided by serial ferritin and transferrin saturation measurements 4

Dietary and Lifestyle Modifications

  • Avoid vitamin C supplements, as these accelerate iron mobilization and increase toxicity 2
  • Avoid alcohol to reduce risk of liver complications 2
  • Avoid raw seafood due to increased risk of Vibrio vulnificus infection in iron-overloaded patients 2
  • Dietary iron restriction is generally unnecessary 4

Treatment Benefits

Phlebotomy can improve heart function, reduce abnormal skin pigmentation, and lessen the risk of liver complications when initiated before end-organ damage occurs. 5, 6

  • Skin pigmentation and cardiac damage may reverse with iron depletion 6
  • Liver damage, endocrine dysfunction, and arthropathy are rarely reversible and may progress despite treatment 6

Follow-Up and Monitoring

For Confirmed Hemochromatosis Patients

  • Monitor serum ferritin and transferrin saturation to guide phlebotomy frequency during maintenance phase 4, 7
  • Screen for hepatocellular carcinoma with ultrasound and alpha-fetoprotein every 6 months in patients with cirrhosis 4
  • Monitor for colorectal and breast cancers, as individuals with hemochromatosis have increased risk 5

For Compound Heterozygotes (C282Y/H63D)

  • If iron studies are normal, perform annual monitoring of ferritin and transferrin saturation due to genetic predisposition 2
  • If iron overload is confirmed, investigate for other contributing causes (alcohol, metabolic syndrome, liver disease) as compound heterozygosity alone rarely causes significant iron accumulation 2
  • Consider phlebotomy only if confirmed iron overload is present, based on individualized clinical assessment 2

Family Screening Protocol

All first-degree relatives of an identified proband should undergo simultaneous HFE genetic testing and phenotypic screening (transferrin saturation and ferritin). 2, 3

  • Test the other parent when screening children of a proband 3
  • Penetrance is higher in family members than in the general population, making screening more cost-effective 3
  • Offer genetic testing after 18 years of age to first-degree relatives 5

Special Considerations

Variable Penetrance

Only 10-50% of C282Y homozygotes develop end-organ damage, with higher penetrance in males and increasing with age 3, 4, 5

Non-Classical Presentations

  • Isolated ferritin elevation with normal transferrin saturation is unusual for classic HFE-related hemochromatosis, which typically presents with elevated TS as the earliest marker 2
  • Genetic testing is still indicated in patients with isolated ferritin elevation to detect non-classical forms 2

MRI for Hepatic Iron Quantification

MRI should be used to quantify hepatic iron concentrations in patients with unclear cause of hyperferritinemia, biochemical iron overload, or positive liver iron staining 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Genetic Testing for Elevated Iron Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Screening and Management of Hemochromatosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Hereditary hemochromatosis.

American family physician, 2013

Research

Hereditary Hemochromatosis: Rapid Evidence Review.

American family physician, 2021

Research

Hereditary hemochromatosis: diagnosis and treatment in primary care.

Tennessee medicine : journal of the Tennessee Medical Association, 1999

Research

Diagnosis and management of hereditary hemochromatosis.

Clinics in liver disease, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.